S. S. Timonova

S. S. Timonova

Auto-generated profile, based on publicly available information

S. S. Timonova

GENERIUM JSC

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
9 April 2022 in Biological Products. Prevention, Diagnosis, Treatment
Verified
Journal Article
Open access
PDF file
STS. S. Timonova
S. S. Timonova
KSK. A. Smolova
K. A. Smolova
DZD. T. Zaripova
D. T. Zaripova
MPM. S. Pantyushenko
M. S. Pantyushenko
MKMariya Koroleva
Mariya Koroleva
VBV. N. Bade
V. N. Bade
Mucopolysaccharidosis type VI (Maroteaux–Lamy syndrome) is an orphan genetic disease caused by deficiency of the lysosomal enzyme arylsulfatase B (ASB). The need to develop a highly productive cell line for the production of recombinant ASB, is behind the concept and relevance of this study. The most promising approach seems to be the development of CHO producer cell lines coexpressing the target ASB enzyme and an auxiliary formylglycine-generating enzyme (FGE). At the same time, it is important from a practical perspective to have the possibility of cultivating producer cell lines as suspensions free of serum or other components of animal origin. The aim of the study was to develop highly productive cell lines for the production of recombinant ASB by coexpression of the auxiliary FGE. Materials and methods: a suspension CHO cell line was used in the study. CHO cells were transfected by electroporation using the MaxCyte STX system. Monoclonal cell lines were obtained with the help of the Cell Metric system. Enzyme-linked immunosorbent assay was used for determination of ASB concentration in the culture fluid. Culture fluid samples were analysed using polyacrylamide gel electrophoresis and Western blotting. The mRNA level was measured by real-time polymerase chain reaction. Results: producer cell lines coexpressing the target ASB enzyme and auxiliary FGE were obtained. An increase in the yield of the active target ASB enzyme from 2 to 100 mg/L was achieved by selecting the optimal ratio of plasmids during transfection. The highest yield of the target ASB enzyme was achieved at the 90:10 ratio (%) of plasmids encoding the ASB and FGE genes, respectively. Conclusions: the authors developed highly productive cell lines for the production of recombinant ASB, which coexpress the target and auxiliary enzymes. The coexpression of ASB and FGE improves the growth and production characteristics of the cell line, probably due to the modification of the ASB active site. The obtained results will help resolve the problem of low enzyme yield, which is typical of this class of medicines.

10 October 2022 in Biological Products. Prevention, Diagnosis, Treatment
Verified
Journal Article
Open access
PDF file
STS. S. Timonova
S. S. Timonova
KSK. A. Smolova
K. A. Smolova
IKI. A. Kirik
I. A. Kirik
MPM. S. Pantyushenko
M. S. Pantyushenko
RAR. L. Anisimov
R. L. Anisimov
VBV. N. Bade
V. N. Bade
Maroteaux—Lamy syndrome (mucopolysaccharidosis type VI) is an orphan genetic disease caused by mutations in the arylsulfatase B gene (ARSB), which encodes the lysosomal enzyme arylsulfatase B (ASB). The relevance of the study lies in the need of a Russian recombinant ASB product for patients with the disease in the Russian Federation. Previously, the authors have developed producer lines coexpressing the target ASB enzyme with an auxiliary formylglycine-generating enzyme (FGE), based on Chinese hamster ovary (CHO) cells. Further development of the recombinant ASB preparation places priority on increasing the enzyme yield. The aim of this study was to increase the productivity of producer clones by optimising the culture process and adding calcium chloride and copper sulfate to the culture medium. Materials and methods: a suspension-adapted CHO cell line was used. Monoclonal cell lines were developed using Cell Metric and ClonePix FL systems. The concentration of ASB in the culture liquid was determined using the enzyme-linked immunosorbent assay (ELISA). The authors analysed batch culture and/or fed-batch culture in media supplemented with various concentrations of copper sulfate and calcium chloride. Results: the combined addition of copper sulfate and calcium chloride at concentrations of 300 μM during batch culture of producer clones coexpressing ASB and FGE increases viability and specific productivity of the cells up to 4.58±1.62 pg/ (cell×day). The cultivation of the lead producer clone coexpressing ASB and FGE under fed-batch conditions for 12 days and the addition of copper sulfate to the growth medium at the concentration of 300 μM allow for increasing the yield of the active lysosomal enzyme, arylsulfatase B, to 420 mg/L. Conclusions: the cultivation of producer clones coexpressing ASB and FGE under fed-batch conditions with copper sulfate added to the medium significantly improves cell line growth properties and the ASB yield. This approach to the selection of culture conditions for producer cell lines can be applied to other enzymes of the sulfatase family.

29 September 2025 in Biological Products. Prevention, Diagnosis, Treatment
Verified
Journal Article
Open access
PDF file
STS. S. Timonova
S. S. Timonova
IKI. A. Kirik
I. A. Kirik
MFM. A. Filatova
M. A. Filatova
AAA. I. Anfilatova
A. I. Anfilatova
SSS. S. Shubina
S. S. Shubina
RKRavil Khamitov
Ravil Khamitov
INTRODUCTION. A key factor in the creation of biotechnological medicinal products is to establish cell lines for high-yield production of recombinant proteins. The development of selection protocols and highly efficient screening approaches for cell lines producing target proteins is a necessary step in the development of recombinant technology for high-yield target protein production.AIM. This study aimed to derive producer cell lines from a CHO suspension cell line for high-yield production of the recombinant monoclonal antibody denosumab.MATERIALS AND METHODS. A CHO-K1 suspension cell line was cultured using serum- and animal component-free media and feeds. The cells were transfected with plasmids containing light and heavy chains of denosumab by electroporation using a MaxCyte STX system. The transfected cells were selected under antibiotic pressure (hygromycin and geneticin). Monoclonal cell lines were obtained using a ClonePix FL system. Leader monoclonal cell lines were identified by determining denosumab concentrations by enzyme-linked immunosorbent assay (ELISA) following fed-batch culture.RESULTS. The optimum concentrations of antibiotics for the selection of CHO-derived denosumab-producing cell lines were 600 mg/L for hygromycin and 600 mg/L for geneticin. The selection process following transfection was successful in 1041 (about 54%) of 1920 minipools. Denosumab-producing minipools were identified by screening culture fluid samples from 96-, 24-, and 6-well plates using ELISA. Then, 23 leader minipools were chosen and adapted to suspension culture in shaker flasks. The growth and production characteristics of these 23 minipools indicated the leader minipool for cloning (mp-19). This minipool provided a denosumab yield of 1.92 g/L on day 7 of fed-batch culture. Using mp-19, the authors obtained monoclonal cell lines providing up to 6.5 g/L denosumab yields on day 9 of fed-batch culture.CONCLUSIONS. The authors obtained monoclonal cell lines for high-yield denosumab production. The offered approach to producer cell line development can be applied to the production of various recombinant proteins, including monoclonal antibodies, enzymes, and blood coagulation factors.

4 July 2026 in Biological Products. Prevention, Diagnosis, Treatment
Verified
Journal Article
Open access
PDF file
STS. S. Timonova
S. S. Timonova
SSS. S. Shubina
S. S. Shubina
JSJ. S. Snegireva
J. S. Snegireva
RAR. L. Anisimov
R. L. Anisimov
NNN. V. Nikiforova
N. V. Nikiforova
РХР. А. Хамитов
Р. А. Хамитов
INTRODUCTION . The development of a biopharmaceutical drug for enzyme replacement therapy based on recombinant acid α-1,4-glucosidase (α-glucosidase) is a pressing task, the solution of which could provide patients with Pompe disease in the Russian Federation with the necessary amount of the drug. This study demonstrates an effective method for developing, from the CHO-K1 cell line, a stable industrial producer clone that produces active α-glucosidase. AIM . This study aimed to develop monoclonal cell lines producing recombinant acid α-glucosidase and to evaluate the stability of growth characteristics and productivity during cultivation over 60 generations. MATERIALS AND METHODS . The suspension CHO-K1 cell line (ECACC) was cultured in BalanCD Growth A medium. Cell transfection was performed by electroporation using the MaxCyte system (according to the CHO protocol). Selection of producers was carried out using puromycin (5 μg/mL). Cloning was performed using a cell dispensing system based on microfluidic technology (C.SIGHT). The monoclonality of the cell lines was confirmed using an automated cell imaging system (Cell Metric CLD). The concentration of α-glucosidase in the culture fluid was determined by enzyme-linked immunosor­bent assay. Enzyme activity was measured by a colorimetric method using the substrate 4-nitrophenyl-α-D-glucopyranoside (pNP-α-D-Glc). RESULTS . Screening of 1000 producers was performed, resulting in the selection of 22 cell lines with a productivity of 0.14–0.65 g/L. The lead α-glucosidase producer GAA-14 was cloned, followed by confirmation of monoclonality. A panel of 20 monoclonal lines was obtained. The specific activity of the enzyme and the mannose-6-phosphate residue (М6Р) content did not differ from those of the reference drug (4.3±0.9 U/mg and 0.99±0.10 mol M6P/mol protein, respectively). When studying the stability of the lead clone over 60 generations, preservation of growth characteristics (viability, 98.5±1.5%; population doubling time, 20.0±1.3 h; and productivity, 450±20 mg/L) was demonstrated under batch cultivation over 7 days. CONCLUSIONS. A stable monoclonal α-glucosidase producer cell line based on CHO-K1 cells has been developed, yielding the active enzyme at 0.45 g/L on day 7. The resulting producer clone is suitable for scale-up and manufacture of the drug substance for preclini­cal studies.

16 October 2026 in Pharmacokinetics and Pharmacodynamics
Verified
Journal Article
Open access
PDF file
SSS. S. Shubina
S. S. Shubina
YGYu. A. Gladchenko
Yu. A. Gladchenko
APA. A. Polupanova
A. A. Polupanova
AAA. I. Anfilatova
A. I. Anfilatova
STS. S. Timonova
S. S. Timonova
СТС. С. Тимонова
С. С. Тимонова
Background. Anti-VEGF agents have proven effective in the treatment of ophthalmological and oncological diseases, and their potential applications continue to grow. Limited availability of commercial bioassay systems for determining the biological activity of anti-VEGF drugs necessitates the development of a proprietary, independent reporter cell line. Objective. To generate a stable reporter cell line expressing vascular endothelial growth factor receptor-2 (KDR) and a firefly luciferase (LUC) reporter gene based on the CHO-K1 suspension cell line. Methods. CHO-K1 (GosNIIGenetika, Russia) was transfected with two plasmids carrying the KDR gene and the LUC gene in varying ratios. The effect of plasmid ratio was assessed by measuring luciferase activity using Promega Bio-Glo kits (Promega, USA) or buffers containing the D-luciferin substrate (Molecta, Russia). VEGF165 (JSC "Generium", Russia) was added to activate the cell line's reporter response. Results. The CHO-KDR/LUC reporter cell line was generated by co-transfecting CHO-K1 cells with plasmids encoding the reporter gene (LUC) and the human VEGFR-2 receptor gene (KDR). Maximum luciferase induction was achieved with a KDR plasmid ratio of 25/75 LUC (%) and reached a plateau of 5x105 RLU; the EC50 was 35.19 ng/mL. Analysis of the luciferase response using homologous ligands demonstrated specificity for VEGF165. With increasing cell generations, growth characteristics and the luciferase response to VEGF165 stimulation remained stable. Conclusion. The CHO-KDR/LUC reporter cell line is suitable for analyzing the biological activity of proteins used in anti-VEGF therapy. Further validation and application will improve the efficiency of developing new therapeutic proteins and biosimilars for VEGF therapy.